Best Drug Development Company in Europe Award
April 08 2010 - 4:26AM
UK Regulatory
TIDMIMM
RNS Number : 8786J
Immupharma PLC
08 April 2010
+------------------------------+-----------------------------------------+
| For Immediate Release | 8 April 2010 |
+------------------------------+-----------------------------------------+
ImmuPharma PLC
("ImmuPharma")
ImmuPharma awarded Best Drug Development Company in Europe Award
ImmuPharma PLC (LSE: IMM) the specialist discovery and development
pharmaceutical company, has been voted "Best Drug Development Company, Europe"
at The New Economy Pharmaceutical & Healthcare Awards 2010.
This award follows on from two notable wins in 2009 namely; "Best Technology
Award" at the AIM Awards, organized by the London Stock Exchange and
"Breakthrough of the year 2009" at the European Mediscience Awards.
- Ends -
For further information please contact:
+--------------------------------------------+--------------------------+
| ImmuPharma PLC | +44 20 7152 4080 |
+--------------------------------------------+--------------------------+
| Dimitri Dimitriou, Chief Executive Officer | |
| | |
| Richard Warr, Chairman | |
+--------------------------------------------+--------------------------+
| | |
+--------------------------------------------+--------------------------+
| Buchanan Communications | +44 20 7466 5000 |
+--------------------------------------------+--------------------------+
| Lisa Baderoon | |
| George Prassas | |
+--------------------------------------------+--------------------------+
| | |
+--------------------------------------------+--------------------------+
| Panmure Gordon & Co | +44 151 243 0963 |
| | |
| Andrew Burnett | |
| Rakesh Sharma | |
+--------------------------------------------+--------------------------+
| | |
+--------------------------------------------+--------------------------+
| Noble & Company Limited | +44 20 7763 2200 |
+--------------------------------------------+--------------------------+
| James Bromhead | |
| | |
+--------------------------------------------+--------------------------+
Notes to Editors:
About ImmuPharma PLC
ImmuPharma is a drug discovery and development group with its key operations in
London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company
aims to develop novel drugs to treat serious medical conditions for which there
is a high unmet need. It has five drugs in development to treat 1) Lupus, 2)
Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5)
Inflammatory and Allergic disorders.
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic,
life-threatening autoimmune disease, was licensed to Cephalon, Inc in a
transaction worth up to $500m in milestone payments in addition to significant
royalties. $45m in cash has been received to date.
The company also has a strong proprietary and collaborative drug development
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAPLPEALEEEF
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
